Tejara Capital Ltd Takes Position in Keros Therapeutics, Inc. $KROS

Key Points

• Tejara Capital Ltd acquired 40,245 shares of Keros Therapeutics, Inc. for approximately $410,000, which now represents about 0.10% of the company's stock.
• Keros Therapeutics posted a quarterly earnings report showing an EPS of ($0.76), surpassing expectations, but its revenue was significantly below estimates at $0.02 million.
• Wall Street analysts have mixed ratings on Keros Therapeutics, with an average price target of $30.00 and seven analysts rating the stock as a "buy."

Tejara Capital Ltd purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 40,245 shares of the company's stock, valued at approximately $410,000. Tejara Capital Ltd owned approximately 0.10% of Keros Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in Keros Therapeutics by 7,690.3% during the first quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock worth $237,000 after buying an additional 2,384 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Keros Therapeutics during the 1st quarter worth approximately $25,000. CWM LLC lifted its position in shares of Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after buying an additional 2,641 shares during the period. Virtus ETF Advisers LLC lifted its position in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after buying an additional 1,998 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its position in shares of Keros Therapeutics by 207.8% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock worth $116,000 after buying an additional 4,976 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.

Analyst Upgrades and Downgrades

KROS has been the subject of several analyst reports. HC Wainwright cut their target price on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Scotiabank cut their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. Wedbush reaffirmed a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research note on Friday, May 30th. Finally, Bank of America cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $32.00 to $18.00 in a research note on Tuesday, June 10th. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $30.00.

Keros Therapeutics Trading Down 1.8%

Shares of Keros Therapeutics stock traded down $0.26 during midday trading on Wednesday, reaching $14.23. The company had a trading volume of 800,164 shares, compared to its average volume of 431,888. The company has a market capitalization of $578.02 million, a price-to-earnings ratio of 45.90, a price-to-earnings-growth ratio of 1.78 and a beta of 1.33. The stock has a fifty day simple moving average of $13.97 and a 200 day simple moving average of $12.93. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.38. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. Keros Therapeutics's revenue for the quarter was up 49002.7% compared to the same quarter last year. During the same quarter last year, the business posted ($1.25) earnings per share. Sell-side analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.